Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posoleucel for Adenovirus Infection Post-Allo-HCT
NCT05179057Phase 3Terminated
- Sponsor
- AlloVir
- Start
- Apr 2022
- Primary completion
- Jan 2024
- Modality
- Native Immune Cells
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in adenovirus infection comparing Posoleucel + SoC with Placebo + SoC (2 arms). Primary endpoints: Number of Participants With Undetectable Adenovirus Infection at Day 43 and Number of Participants Who Experienced Treatment-emergent Adverse Events at 34 weeks. Started Apr 2022; status: terminated.
02
Drugs
posoleucel
03
Conditions
adenovirus infection
Beyond the preview
Go deeper on NCT05179057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05179057.